Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label Multicenter Study of AM003 Dose Escalation, Administered Intratumorally to Patients With Locally Advanced and Metastatic Solid Tumors

NCT06258330 is registered in ClinicalTrials.gov with Aummune Ltd. as lead sponsor.

NCT NCT06258330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06258330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label Multicenter Study of AM003 Dose Escalation, Administered Intratumorally to Patients With Locally Advanced and Metastatic Solid Tumors
Lead sponsor
Aummune Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2022
Completion date
October 1, 2024
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor